MYC and neoplasm: Direct inhibition of c-Myc has been shown to trigger rapid tumor regression in mice with fully reversible side effects, suggesting that regulation of c-Myc by directly targeting it or through inhibition of PIM kinases is a viable targeted therapeutic strategy in cancer.